Mercury Biopharmaceutical Corporation (TPEX:6932)
Taiwan
· Delayed Price · Currency is TWD 12.90
+0.30 (2.38%)
Apr 24, 2025, 1:28 PM CST
Mercury Biopharmaceutical Revenue
In the year 2024, Mercury Biopharmaceutical had annual revenue of 4.96M TWD with 380.45% growth. Mercury Biopharmaceutical had revenue of 246.00K in the half year ending December 31, 2024, a decrease of -90.82%.
Revenue
4.96M
Revenue Growth
+380.45%
P/S Ratio
1,092.23
Revenue / Employee
n/a
Employees
n/a
Market Cap
5.42B
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| PharmaEssentia | 9.73B |
| Caliway Biopharmaceuticals | 44.43M |
| Bora Pharmaceuticals Co., LTD. | 19.25B |
| Lotus Pharmaceutical | 18.58B |
| Polaris Group | 107.00M |
| Oneness Biotech | 117.93M |
| Pegavision | 6.82B |
| Lumosa Therapeutics | 39.15M |